Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
OBJECTIVE
To investigate the efficacy of reducing the drop-skin contact to prevent dermatologic side effects of bimatoprost 0.03% topical therapy.


METHODS
Prospective, randomized, single-blinded, internally controlled study.


METHODS
Enrolled subjects started bimatoprost 0.03% therapy once at night in both eyes and were instructed to wipe selectively only one eye (eye 1) with an adsorbent pad during and after drops administration for four months. The fellow eye acted as the internal control. Eyelash growth, regional skin hypertrichosis, and pigmentation on the periocular skin were assessed at baseline and during the four months of follow-up.


RESULTS
A lower incidence of eyelash growth and skin pigmentation in the inferonasal pericanthal region were observed in eye 1. The incidence of pigmentation in the inferotemporal skin region and skin hypertrichosis were similar in the two eyes.


CONCLUSIONS
The reduction of the drop-skin contact affects the regional incidence and the extent of dermatologic skin changes that are related to bimatoprost 0.03% topical therapy.
Centofanti
Marco
M
Department of Ophthalmology, University of Tor Vergata, Rome, Italy.
Oddone
Francesco
F
Chimenti
Sergio
S
Tanga
Lucia
L
Citarella
Luigi
L
Manni
Gianluca
G
D000328:Adult; D000368:Aged; D000577:Amides / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069580:Bimatoprost; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004209:Disposable Equipment; D005140:Eyelashes / Q000187:drug effects; D005141:Eyelid Diseases / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006201:Hair Diseases / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced / Q000517:prevention & control*; D007429:Intraocular Pressure / Q000187:drug effects; D008055:Lipids / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use; D009885:Ophthalmology / Q000379:methods; D011446:Prospective Studies; D016037:Single-Blind Method; D017592:Skin Care / Q000295:instrumentation*; D012880:Skin Pigmentation / Q000187:drug effects
D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D000069580:Bimatoprost